Gila Therapeutics Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
2
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$356K
- Investors
-
8
Gila Therapeutics General Information
Description
Operator of a clinical-stage pharmaceutical company intended to treat obesity and prevent weight gain. The company develops and commercializes innovative, effective, and safe therapies for metabolic diseases, using novel routes of administration, thereby enabling people to lose weight and decrease calorie intake in a non-invasive and non-absorbed manner.
Contact Information
Website
www.gilatherapeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Technology Systems
Biotechnology
Primary Office
- One Financial Center
- Boston, MA 02111
- United States
+1 (612) 000-0000
Gila Therapeutics Timeline
Gila Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 29-Nov-2022 | $356K | 00.00 | Completed | Clinical Trials - General | |
| 7. Later Stage VC | 01-Mar-2022 | 00.000 | Completed | Clinical Trials - General | ||
| 6. Later Stage VC | 12-Nov-2021 | 00.000 | 00.000 | Completed | Clinical Trials - General | |
| 5. Later Stage VC | 29-Jan-2021 | 00000 | 00.00 | Completed | Startup | |
| 4. Later Stage VC | 11-Mar-2019 | 00000 | 00.000 | Completed | Startup | |
| 3. Accelerator/Incubator | 000 | Completed | Startup | |||
| 2. Early Stage VC (Series A) | 02-Mar-2017 | $4M | $4M | 000.00 | Completed | Startup |
| 1. Spin-Off | 01-Jan-2014 | Completed | Startup |
Gila Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 0,000,000 | 00.000000 | 00.00 | 00.0 | 00.0 | 00 | 00.0 | 00.000 |
Gila Therapeutics Patents
Gila Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3087733-A1 | Peptide yy pharmaceutical formulations, compositions, and methods | Pending | 23-Jan-2018 | 000000000 | |
| EP-3743092-A1 | Peptide yy pharmaceutical formulations, compositions, and methods | Pending | 23-Jan-2018 | 000000000 | |
| EP-3743092-A4 | Peptide yy pharmaceutical formulations, compositions, and methods | Pending | 23-Jan-2018 | 000000000 | 0 |
| JP-2021512051-A | Peptide yy pharmaceutical preparations, compositions, and methods | Pending | 23-Jan-2018 | 000000000 | 0 |
| US-20220143146-A1 | Peptide yy pharmaceutical formulations, compositions, and methods | Pending | 23-Jan-2018 | A61K38/22 | 0 |
Gila Therapeutics Executive Team (6)
Gila Therapeutics Board Members (4)
| Name | Representing | Role | Since |
|---|---|---|---|
| Christopher DeSouza | Self | Board Member | 000 0000 |
| Richard Horan | Self | Board Member | 000 0000 |
| Scott Schorer | Self | Chief Executive Officer, President & Board Member | 000 0000 |
| Timothy Barberich | Self | Board Member | 000 0000 |
Gila Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Gila Therapeutics Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| John Lilly Strategic Insights | Corporation | Minority | 000 0000 | 000000 0 | |
| Lateral Capital Management | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Argonautic Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Broadview Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Harvard Business School Alumni Angels of Chicago | Angel Group | Minority | 000 0000 | 000000 0 |